Slide 1: Brenntag
> BRENNTAG
Slide 2: FY 2024 Results Presentation: Highlights FY 2024
FY 2024 Results 1. Highlights FY 2024 Presentation
Slide 3: Highlights FY 2024
Highlights FY 2024 SALES EUR 16.2 bn -3.2% vs. PY (fx adj.) EPS EUR 3.71 FY 2023: EUR 4.73 OPERATING GROSS PROFIT EUR 4.0 bn -0.2% vs. PY (fx adj.) DPS PROPOSAL EUR 2.10 FY 2023: EUR 2.10 OPERATING EBITA EUR 1,102 m -12.5% vs. PY (Fx adj.) BUSINESS ENVIRONMENT Challenging Markets Continued intense c
Slide 4: FY 2024 Results: Strategy update
FY 2024 Results Presentation 2. Strategy update
Slide 5: FY 2024 Strategy Update
FY 2024 Strategy Update oy Main Achievements Further successful execution of Horizon 2 Strategy Targeted disentanglement in areas with the highest value creation and differentiation potential SV Prudently managing cost base and executing cost containment measures SV DiDEX well on track an Division u
Slide 6: Cost-out and DiDEX update
Cost-out and DiDEX update Recap Cost-out and DiDEX parameters Cost-out program EUR ~300 m one-off cost for cost-out and @ One-off costs to achieve cost containment and disentanglement targeted disentanglement ~ * || © ‘ : 4 (reported below Op. EBITA) EUR ~50 m in 2024, EUR ~100 m expected for 2025 °
Slide 7: FY 2024 Results: Financial performance FY 2024
FY 2024 Results Presentation 3. Financial performance FY 2024
Slide 8: Operating EBITA bridges
Financials FY 2024: Operating EBITA bridges” Operating EBITA growth in EURm -13% 5 si | -189 FY 2023 FX translation M&A Organic FY 2024 contribution growth FX translation As Hi M&A contribution Operating EBITA growth by division inEURm -14% -13% | FY 2023 Brenntag Brenntag Group and Specialties Esse
Slide 9: Brenntag Specialties
Financials FY 2024: Brenntag Specialties Operating EBITA growth vs. PY Stable volumes in combination with slightly lower Gross Profit per unit Life Science Material Science -9.0% -8.4% ) | 7 G : All business units in Life Science except B&C saw negative operating CASE” & Construction Gross Profit de
Slide 10: Brenntag Essentials
Financials FY 2024: Brenntag Essentials Operating EBITA growth vs. PY Positive volume developments offset lower Gross Profit per unit NORTH AMERICA EMEA Operating Gross Profit of EUR 2,852 m, an increase of 0.2% vs. PY = 9, cq 0, 10.0 Yo 12.6 %o Operating EBITA of EUR781 m, a decrease of 14.1% vs. P
Slide 11: Income statement
Financials FY 2024: Income statement in EURM FY 2023 A AFX adjusted Sales 16,237.4 16,815.1 -3.4% -3.2% Cost of materials -12,212.0 -12,773.3 44% 4.2% 4,025.4 4,041.8 0.4% -0.2% Operating expenses -2,568.6 -2,457.2 45% 47% 1,456.8 1,584.6 -8.1% -7.8% Depreciation -354.9 -319.6 11.0% 11.0% 1,101.9 1,
Slide 12: OPEX bridge
Financials FY 2024: OPEX bridge” Operating expense development in EURm 4.7% ~15 — M&A driven increase combined with DiDEX & IT investments leading to cost increase against prior-year Underlying OPEX increase related to higher personnel expenses, driven by wage inflation and volume related cost incre
Slide 13: Free cash flow and ROCE
Financials FY 2024: Free cash flow and ROCE in EURM FY 2023 Aabs. 0% Payments to acquire intangible assets and property, plant and equipment -342.2 -321.1 -21.1 6.6% A Working capital -45.8 608.7 -654.5 -107.5% Principal and interest payments on lease liabilities -176.2 -160.2 -16.0 10.0% Working ca
Slide 14: Balance sheet and maturity profile
Financials FY 2024: Balance sheet and maturity profile in EURm EMBplteriiye 31 Dec 2023 Financial liabilities 2,939.0 Lease liabilities 617.3 ./. Cash and cash equivalents 763.3 Net Debt 2,793.0 Equity 4,762.0 2,313.9 449.8 576.9 2,186.8 14x 4,356.7 Eurobond & in EUR m?) Promissory Note Etropenc Eur
Slide 15: Outlook 2025
Outlook 2025 Brenntag Group FX impact Tax rate: CAPEX | Comments FY 2025 Outlook EUR 1,100 million to 1,300 millionYEBITA EUR/USD: ~1.05 (2024: ~1.08) Sensitivity (FY basis): Delta of EUR/USD +/- 1 cent = EUR ~ -/+ 10 m operating EBITA Tax rate: 28-30% EUR ~300 m Brenntag expects a challenging busin
Slide 16: Dr. Christian Kohlpaintner CEO, Dr. Kristin Neumann CFO
Dr. Christian Kohlpaintner Dr. Kristin Neumann CEO CFO 1
Slide 17: FY 2024 Results: Appendix
FY 2024 Results Presentation 4. Appendix
Slide 18: Segments
Financials FY 2024: Segments inEURm Operating Gross Profit? FY 2023 Specialties Life Science 829.9 843.3 Specialties Material Science 325.4 328.7 Specialties Other 17.9 25.9 41732 1,197.9 Essentials EMEA 994.7 986.4 Essentials North America 1,536.8 1,532.9 Essentials Latin America 166.6 162.5 Essent
Slide 19: Cash flow statement
Financials FY 2024: Cash flow statement inEURm Profit after tax Effect from IAS 29 on profit/loss after tax Depreciation & amortization Income tax expense Income taxes paid Net interest expense Interest paid (thereof interest paid for leases) Interest received Dividends received Changes in working c
Slide 20: Cash flow statement (continued)
Financials FY 2024: Cash flow statement (continued) in EURm FY 2024 FY 2023 Proceeds from the disposal of consolidated subsidiaries and other business units less costs to sell - 8.1 Proceeds from the disposal of other financial assets 0.4 Proceeds from the disposal of intangible assets and property,
Slide 21: Working capital
Financials FY 2024: Working capital in EURm Inventories 1,518.4 + Trade receivables 2,282.5 ./. Trade payables 1,661.6 Working capital (end of pe: 2,139.3 Working capital turnover (annualized)?) 7.6x a 2 Based on fx. effects as of end of respective reporting period and incl. M&A 21 30 Sep 2024 1,514
Slide 22: HC bridge 2019-2024
HC bridge 2019-2024 Headcount 19-24 1,801 -916 Headcount reduction since 2019 in context of Project Brenntag 17,492 Total headcount increase since 2020 purely M&A driven 17,237 Organic headcount reduction from 2020 to 2024, despite strategic increase in core group functions and DiDEX Further intend
Slide 23: Operating EBITA bridges Q4 2024
Financials Q4 2024: Operating EBITA bridges” Operating EBITA growth inEURm 4 12 e -39 Q4 2023 FX translation M&A Organic contribution growth FX translation li M&A contribution Q4 2024 BB Organic Growth Operating EBITA growth by division inEURm -~6% -9% -9% | Q4 2023 Brenntag Brenntag Group and Speci
Slide 24: Segments Q4 2024
Financials Q4 2024: Segments inEURm Operating Gross Profit? Q42023 Specialties Life Science 208.4 199.2 Specialties Material Science 776 74.0 Specialties Other 2.6 6.0 Essentials EMEA 245.5 232.0 Essentials North America 376.0 380.5 Essentials Latin America 45.3 42.2 Essentials APAC 36.2 35.9 Essent
Slide 25: Income statement Q4 2024
Financials Q4 2024: Income statement in EURMm Q4.2023 A AFX adjusted Sales 3,989.7 3,943.1 1.2% 0.2% Cost of materials -2,995.8 -2,968.3 0.9% -0.1% 993.9 974.8 2.0% 0.9% Operating expenses -635.5 -601.2 -5.7% -4,9% 358.4 373.6 4.1% 5.5% Depreciation -94.4 -88.6 6.5% 5.5% 264.0 285.0 7.4% -8.9% Net i
Slide 26: Cash flow statement Q4 2024
Financials Q4 2024: Cash flow statement Profit after tax 128.7 137.3 Effect from IAS 29 on profit/loss after tax 44 15 Depreciation & amortization 103.4 Income tax expense 70.9 Income taxes paid -36.3 Net interest expense 26.5 Interest paid -29.9 (thereof interest paid for leases) (-4.5) Interest re
Slide 27: Cash flow statement (continued) Q4 2024
Financials Q4 2024: Cash flow statement (continued) inEURMm Q4 2024 Q4 2023 Proceeds from the disposal of consolidated subsidiaries and other business units less cost to sell - 8.1 Proceeds from the disposal of other financial assets 0.4 0.2 Proceeds from the disposal of intangible assets and proper
Slide 28: Free cash flow Q4 2024
Financials Q4 2024: Free cash flow in EURm Q4 2024 Payments to acquire intangible assets and property, plant and equipment -120.0 A Working capita 119.4 Principal and interest payments on lease liabilities -44.8 G@) 28° Based on average fx rate excl. M&A Q4 2023 373.6 -159.8 221.0 ~45.3 389.5 Aabs -
Slide 29: Financial calendar / contact
Financial calendar / contact Financial calendar Contact Follow us: in| May 14, 2025 May 22, 2025 Brenntag SE Quarterly Statement Annual General Corporate Investor Relations Q1 2025 Meeting Phone: +49 (0) 201 6496 2100 Fax: +49 (0) 201 6496 2003 August 13, 2025 November 12, 2025 Half-Year Financial R
Slide 30: Disclaimer
Disclaimer This presentation may contain forward-looking statements based on current assumptions and forecasts made by Brenntag SE and other information currently available to the company. Various known and unknown risks, uncertainties and other factors could lead to material differences between the